162 related articles for article (PubMed ID: 20675405)
1. Drug metabolism and pharmacokinetics of 4-substituted methoxybenzoyl-aryl-thiazoles.
Li CM; Lu Y; Narayanan R; Miller DD; Dalton JT
Drug Metab Dispos; 2010 Nov; 38(11):2032-9. PubMed ID: 20675405
[TBL] [Abstract][Full Text] [Related]
2. Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice.
Ahn S; Kearbey JD; Li CM; Duke CB; Miller DD; Dalton JT
Drug Metab Dispos; 2011 Apr; 39(4):636-43. PubMed ID: 21233217
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability.
Li CM; Chen J; Lu Y; Narayanan R; Parke DN; Li W; Ahn S; Miller DD; Dalton JT
Drug Metab Dispos; 2011 Oct; 39(10):1833-9. PubMed ID: 21742898
[TBL] [Abstract][Full Text] [Related]
5. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
7. The In vitro hepatic metabolism of quinine in mice, rats and dogs: comparison with human liver microsomes.
Zhao XJ; Ishizaki T
J Pharmacol Exp Ther; 1997 Dec; 283(3):1168-76. PubMed ID: 9399990
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
[TBL] [Abstract][Full Text] [Related]
9. Bioactivation of isothiazoles: minimizing the risk of potential toxicity in drug discovery.
Teffera Y; Choquette D; Liu J; Colletti AE; Hollis LS; Lin MH; Zhao Z
Chem Res Toxicol; 2010 Nov; 23(11):1743-52. PubMed ID: 20825217
[TBL] [Abstract][Full Text] [Related]
10. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, pharmacodynamics and metabolism of a novel anticancer agent for prostate cancer.
Yang J; Ahn S; Wu Z; Hwang DJ; Miller DD; Dalton JT
Int J Oncol; 2012 Jul; 41(1):337-44. PubMed ID: 22576690
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
Fura A; Khanna A; Vyas V; Koplowitz B; Chang SY; Caporuscio C; Boulton DW; Christopher LJ; Chadwick KD; Hamann LG; Humphreys WG; Kirby M
Drug Metab Dispos; 2009 Jun; 37(6):1164-71. PubMed ID: 19251818
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.
Wang H; Li M; Rhie JK; Hockenbery DM; Covey JM; Zhang R; Hill DL
Cancer Chemother Pharmacol; 2005 Sep; 56(3):291-8. PubMed ID: 15883820
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
[TBL] [Abstract][Full Text] [Related]
15. Stereoselective metabolism of tazofelone, an anti-inflammatory bowel disease agent, in rats and dogs and in human liver microsomes.
Clay MP; Hanssen BR; Surapaneni SS; Lindstrom TD
Chirality; 1999; 11(3):233-40. PubMed ID: 10079502
[TBL] [Abstract][Full Text] [Related]
16. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data.
Izumi T; Hosiyama K; Enomoto S; Sasahara K; Sugiyama Y
J Pharmacol Exp Ther; 1997 Mar; 280(3):1392-400. PubMed ID: 9067328
[TBL] [Abstract][Full Text] [Related]
18. In vitro metabolic studies on the selective metabotropic glutamate receptor sub-type 5 (mGluR5) antagonist 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl]-pyridine (MTEP).
Green MD; Yang X; Cramer M; King CD
Neurosci Lett; 2006 Jan; 391(3):91-5. PubMed ID: 16153770
[TBL] [Abstract][Full Text] [Related]
19. Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor.
Eng H; Niosi M; McDonald TS; Wolford A; Chen Y; Simila ST; Bauman JN; Warmus J; Kalgutkar AS
Xenobiotica; 2010 Jun; 40(6):369-80. PubMed ID: 20297923
[TBL] [Abstract][Full Text] [Related]
20. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans.
Naritomi Y; Terashita S; Kimura S; Suzuki A; Kagayama A; Sugiyama Y
Drug Metab Dispos; 2001 Oct; 29(10):1316-24. PubMed ID: 11560875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]